Rituximab，Lenalidomide and Chidamide Followed by CR-CHOP in Elderly Patients with Newly-diagnosed Double-expressor Lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 44
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.
详细描述
It is divided into 4 stages: screening period, induction therapy period, immunochemotherapy period and maintenance therapy period. The screening period was 28 days before the first dose. Introduction treatment period: Enrolled subjects received RLC regimen every 21 days for a cycle of 2 cycles. Immunochemotherapy phase: CR-miniCHOP regimen was administered after the completion of the introduction therapy phase. Every 21 days for a cycle, treatment for 4 cycles. Patients who achieved CR with induction therapy entered the maintenance treatment period, receiving 20 mg of chidamide d1,4,8,11 recommended 8 cycles. Patients who did not achieve CR were discontinued from the study and treated at the discretion of their physician.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 65 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Untreated DLBCL patients confirmed by histopathology
- •Immunohistochemistry showed positive expression of MYC and BCL2 protein (double expressor lymphoma, MYC≥40%, BCL2≥50%)
- •age over 70 years old or age ≥65 years old and ECOG score ≥2 points, both male and female
- •Having at least one evaluable lesion, defined as having at least one lymphadenopathy with a maximum diameter > 1.5 cm, or at least one extranodal lesion with a maximum diameter > 1.0 cm, and at least two vertical diameters that can be accurately measured.
- •Expected survival time ≥3 months
- •voluntary participation in clinical research; Fully understand and understand the study and sign the informed consent; Willingness to follow and ability to complete all research steps.
排除标准
- •The pathological subtypes were PCNSL, PMBCL, EBV-positive DLBCL and HGBL
- •Hemophagocytic syndrome accompanied the diagnosis
- •Central nervous system involvement is secondary to lymphoma
- •Are participating in other clinical studies, or the first study drug is administered less than 4 weeks after the end of treatment in the previous clinical study
- •HIV infection
- •Major surgery was performed within 28 days prior to study start
- •Any active infection that required systematic anti-infective therapy developed within 14 days prior to study initiation
- •The patients considered by the investigator to be unsuitable for participating in this study
研究组 & 干预措施
RLC-CRCHOP
Introduction treatment: Rituximab, lenalidomide, chidamide for 2 cycles:
rituximab 375mg/m2, d1, lenalidomide 10mg qd d1-14, chidamide 20mg, d1,4,8,11.
Immunochemtherapy phase: CR CHOP for 4 cycles: chidamide 20mg d1,4,8,11,rituximab 375mg/m2 d0, cyclophosphamide: 750mg/m2 d1, epirubicin: 75mg/ m2 d1 (or liposomal doxorubicin 35mg/m2 d1), vindesine 4mg d1, prednisone: 100mg, d1-5.
maintenance treatment period: chidamide d1,4,8,11
干预措施: RLC-CRCHOP (Drug)
结局指标
主要结局
PFS
时间窗: From date of first day of treatment until the date of first documented date of disease progression or death from any cause, assessed up to 24 months
Progression Free Survival
次要结局
- ORR(21days after the end of treatment)
- CRR(21days after the end of treatment)
- OS(: From date of first day of treatment until the date of first documented date of death from any cause, assessed up to 24 months)
- AE and SAE(From date of first day of treatment until 30 day after last treatment)
- Performance status(At screening period, after 2 cycles of ZR2 regimen(each cycle is 21 days), after 2 cycles of RCHOP regimen(each cycle is 21 days) and 21days after the end of treatment)
研究者
Yang haiyan
Chief director of Lymphoma Department
Zhejiang Cancer Hospital